Considered and approved the standalone Un-audited financial results of the company for the quarter ended on 30th June 2026.

14th August, 2026 The Manager, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code: 539206; Company Symbol: GVBL Sub: Outcome of the Board meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on today i.e. 14th August 2026. Dear Sir/Madam, This is to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 14th August 2026, at the Corporate office of the Company situated at G-74, Pushkar Enclave, Paschim Vihar, Delhi - 110063 to consider and approve the following matter(s): - 1. Considered and approved the standalone Un-audited financial results of the company for the quarter ended on 30th June 2026. A copy of the said standalone un-audited financial results along with the Limited review report from Statutory Auditor thereon is enclosed herewith. The meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 03:40 P.M. This is for your information and record please. Thanking you, Yours sincerely, For Genomic Valley Biotech Limited Yogesh Agrawal Managing Director DIN : 01165288 ANDROS & CO. 90L , Pearls Omaxe,PIot B-1 Chartered Accountants NSP , Pitampura , Delhi 110034 Email: briibhushan_ca @yah oo,co.in Phone 47068981, 9811075811 LIMITED REVIEW REPORT The Baard of Directors of Genomic Valley Biotech Limited, 4 K.M" Stone, Berri Chharra Road, Village- Kherka Musalman, P.O. Tandaheri, Tehlil- Bahadurgarh, District-|haiiar, Haryana- XZ45*7 . 1. Introduction We have reviewed the accompanying statement of unaudited financial results for the Quarter ended on fune 3A,ZA26 ('the statement') of Genomic Valley Biotech Limited ['the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, as amended ("Listing Regulations"). This Statement is the responsibility of the Cornpany's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and rneasurement principles laid down in the Indian Accounting Standard 34 ('lnd AS 34'J, Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2AL3, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 2. Scope o.f Review We Conducted our review in accordance with the Standard on Review Engagements (SRE) 241A, 'Review of lnterim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing (Sas) and consequently hoes not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express and audit opinion. 3. Conclusion Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable Indian Accounting Standard ('lnd AS') prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2AL5, including the manner in which it is to be disclosed, or that it contains any material misstatement. For ANDROS & CO. Chartered Accountants FRN: 008976N ICA Brii bhushan Garg) (Partner) (Membership No.-084865) Place: Delhi Date: 1+-08-2 07-6 Peer Review certificate no: 019517 : 2608 4865-IITXCX -4853 UDIN